Wide Ranks

HOOK

HOOKIPA Pharma Inc.

2.48

Top Statistics
Market Cap 29 M Forward PE -0.5167 Revenue Growth -51.80 %
Current Ratio 3.86 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -93.16 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.7560 Enterprise / Revenue -0.6920 Price To Sales Trailing12 Months 0.5731
Profitability
Profit Margins -93.16 % Operating Margins -1736.74 %
Balance Sheet
Total Cash 77 M Total Cash Per Share 6.40 Total Debt 4 M
Total Debt To Equity 5.69 Current Ratio 3.86 Book Value Per Share 7.45
All Measures
Short Ratio 108.00 % Message Board Id finmb_571641905 Shares Short Prior Month 35190
Return On Equity -0.4899 City New York Uuid 4fc7c674-d2aa-3bcd-a128-4deb756f8490
Previous Close 2.32 First Trade Date Epoch Utc 1 B Book Value 7.45
Beta 0.8290 Total Debt 4 M Volume 62763
Price To Book 0.3327 Last Split Date 1 B Fifty Two Week Low 2.08
Total Cash Per Share 6.40 Total Revenue 52 M Shares Short Previous Month Date 1 B
Target Median Price 44.00 Max Age 86400 Recommendation Mean 1.75
Sand P52 Week Change 0.3133 Operating Margins -1736.74 % Target Mean Price 38.75
Net Income To Common -48596000 Short Percent Of Float 0.0047 Implied Shares Outstanding 12 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 89670
Average Volume10days 89670 Total Cash 77 M Next Fiscal Year End 1 B
Revenue Per Share 4.40 Held Percent Insiders 0.2144 Ebitda Margins -91.46 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 2.32 Target Low Price 7.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.70 Open 2.39 Free Cashflow -46046000
State NY Dividend Yield 0.00 % Return On Assets -0.2010
Time Zone Short Name EST Trailing Eps -3.67 Day Low 2.33
Address1 350 Fifth Avenue Shares Outstanding 9 M Price Hint 4
Target High Price 60.00 Website https://www.hookipapharma.com 52 Week Change -0.5641
Average Volume 43567 Forward Eps -5.43 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 358.20 % Last Split Factor 1:10
Regular Market Day High 2.50 Is_sp_500 False Profit Margins -93.16 %
Debt To Equity 5.69 Fifty Two Week High 11.30 Day High 2.50
Shares Short 36244 Regular Market Open 2.39 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -0.6920 Revenue Growth -51.80 %
Shares Percent Shares Out 0.0037 Operating Cashflow -73875000 Currency USD
Time Zone Full Name America/New_York Market Cap 29 M Is_nasdaq_100 False
Zip 10118 Quote Type EQUITY Industry Biotechnology
Long Name HOOKIPA Pharma Inc. Regular Market Day Low 2.33 Held Percent Institutions 0.3716
Current Price 2.48 Address2 72nd Floor Suite 7240 Enterprise To Ebitda 0.7560
Financial Currency USD Current Ratio 3.86 Gross Margins -62.05 %
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 6 M Two Hundred Day Average 6.05 Enterprise Value -36088384
Price To Sales Trailing12 Months 0.5731 Forward PE -0.5167 Regular Market Volume 62763
Ebitda -47709000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.

The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers.

Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial.

The company's preclinical stage products include HB-300 program for prostate cancer.

It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus.

HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.